Gcore Unveils Inference at the Edge – Bringing AI Applications Closer to End Users for Seamless Real-Time Performance
6.6.2024 11:30:00 EEST | Business Wire | Press release
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the launch of Gcore Inference at the Edge, a breakthrough solution that provides ultra-low latency experiences for AI applications. This innovative solution enables the distributed deployment of pre-trained machine learning (ML) models to edge inference nodes, ensuring seamless, real-time inference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606719181/en/
Gcore Inference at the Edge empowers businesses across diverse industries with cost-effective, scalable, and secure AI model deployment (Graphic: Gcore)
Gcore Inference at the Edge empowers businesses across diverse industries—including automotive, manufacturing, retail, and technology—with cost-effective, scalable, and secure AI model deployment. Use cases such as generative AI, object recognition, real-time behavioural analysis, virtual assistants, and production monitoring can now be rapidly realised on a global scale.
Gcore Inference at the Edge runs on Gcore's extensive global network of 180+ edge nodes, all interconnected by Gcore's sophisticated low-latency smart routing technology. Each high-performance node sits at the edge of the Gcore network, strategically placing servers close to end users. Inference at the Edge runs on NVIDIA L40S GPUs, the market-leading chip designed specifically for AI inference. When a user sends a request, an edge node determines the route to the nearest available inference region with the lowest latency, achieving a typical response time of under 30 ms.
The new solution supports a wide range of fundamental ML and custom models. Available open-source foundation models in the Gcore ML Model Hub include LLaMA Pro 8B, Mistral 7B, and Stable-Diffusion XL. Models can be selected and trained agnostically to suit any use case, before distributing them globally to Gcore Inference at the Edge nodes. This addresses a significant challenge faced by development teams where AI models are typically run on the same servers they were trained on, resulting in poor performance.
Benefits of Gcore Inference at the Edge include:
- Cost-effective deployment: A flexible pricing structure ensures customers only pay for the resources they use.
- Inbuilt DDoS protection: ML endpoints are automatically protected from DDoS attacks through Gcore’s infrastructure.
- Outstanding data privacy and security: The solution features built-in compliance with GDPR, PCI DSS, and ISO/IEC 27001 standards.
- Model autoscaling: Autoscaling is available to handle load spikes, so a model is always ready to support peak demand and unexpected surges.
- Unlimited object storage: Scalable S3-compatible cloud storage that grows with evolving model needs.
Andre Reitenbach, CEO at Gcore comments: “Gcore Inference at the Edge empowers customers to focus on getting their machine learning models trained, rather than worrying about the costs, skills, and infrastructure required to deploy AI applications globally. At Gcore, we believe the edge is where the best performance and end-user experiences are achieved, and that is why we are continuously innovating to ensure every customer receives unparalleled scale and performance. Gcore Inference at the Edge delivers all the power with none of the headache, providing a modern, effective, and efficient AI inference experience.”
Learn more at https://gcore.com/inference-at-the-edge
About Gcore
Gcore is the global edge AI, cloud, network, and security solutions provider. Gcore provides its solutions to global leaders in numerous industries. The company manages its own global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM, due to the average response time of 30 ms worldwide. Gcore’s network consists of 180+ points of presence around the world in reliable Tier IV and Tier III data centres, with a total capacity exceeding 200 Tbps.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606719181/en/
Contact information
Gcore press contact
pr@gcore.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 16:00:00 EEST | Press release
Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized authority on applied AI, she is a Gartner-recognized thought leader and author on AI SaaS and product en
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 09:00:00 EEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 06:49:00 EEST | Press release
Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 20:48:00 EEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
